The market observed a sharp increase in Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares after the company revealed a noteworthy intellectual property milestone. The stock of ENSC was up 81.28% on the charts at $3.39 as of the most recent trading update.
Patent Approved for Novel Treatment of Opioid Use Disorder
Following Ensysce’s receipt of a Notice of Allowance from the U.S. invention and Trademark Office for its invention entitled “Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof,” investor confidence has surged. The formulation and method of use claims for its innovative therapeutic drug, PF9001, are covered by this patent.
PF9001, which was created using Ensysce’s own TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) platforms, is a novel strategy for combating the continuing opioid crisis.
A Safer Substitute for Conventional Methadone Treatment
Despite being commonly used to treat opioid use disorder (OUD), methadone has come under fire for probable overdose, respiratory depression, and heart problems. With its targeted release mechanism, which provides overdose protection and a consistent, once-daily dosage profile, PF9001 seeks to lessen these risks. Early data suggests a significant reduction in cardiotoxicity risks, bolstering the credibility of Ensysce’s overdose prevention technology.
Expert Endorsement and Institutional Support
The significance of such breakthroughs was emphasized by Dr. Richard Dart, the director of the Rocky Mountain Poison and Drug Center and a renowned expert in toxicology and emergency care. He pointed out that by lowering the risk of overdose, the use of MPAR technology with methadone analogs may save lives.
Path Forward with Federal Backing
Extensive research efforts to improve treatment results for OUD patients led to the creation of PF9001. The National Institute on Drug Abuse (NIDA) has acknowledged the initiative and provided funding, confirming its potential to improve public health. In the battle against opioid dependence, Ensysce (ENSC) thinks PF9001 might greatly increase patient compliance and yield better treatment outcomes.
